Giancamilli, Brown honored at NACDS Annual
PALM BEACH, Fla. — On the final evening of the National Association of Chain Drug Stores’ annual meeting in Palm Beach, Fla., the organization honored two industry leaders with chain pharmacy’s highest honors.
NACDS recognized Andrew Giancamilli, former Rexall Pharma Plus CEO and past NACDS chairman, with the Sheldon W. Fantle Lifetime Achievement Award. M. Jerome Brown, former Unilever VP industry and customer development, received the Robert B. Begley Award.
Giancamilli’s career in health care includes more than 35 years at Perry Drug Stores (after graduating pharmacy school), as well as executive capacities at Kmart and Canadian Tire, prior to his tenure at Katz Group, where he served as CEO of Synders Drug Stores and Rexall Pharma Plus.
Meanwhile, Brown, who started at Johnson & Johnson in 1972, joined Unilever (previously called Chesebrough-Pond’s) in 1980. He most recently served as VP and leader of Unilever’s industry and customer development team for Unilever home and personal care until his retirement in this year.
The Sheldon W. Fantle Lifetime Achievement Award was established in 1989 to recognize exceptional accomplishments and contributions to the industry. It was renamed in 1996, in honor of Bud Fantle, People’s Drug Stores. Meanwhile, the Begley Award, which was established in 1980, is named in memory of former NACDS board chairman Robert B. Begley. It honors an individual who possess qualities of great personal warmth, generous spirit and long-time service to the chain pharmacy industry.
"Andy Giancamilli and Jerry Brown are two of the industry’s finest leaders, each playing an important role in the evolution of retail pharmacy over the last four decades," NACDS president and CEO Steve Anderson said. "They each leave behind a legacy of commitment and passion to their companies and the industry, and we are honored to commemorate them with chain pharmacy’s highest honors."
Sun launches generic version of Zyprexa
MUMBAI, India — Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.
Sun announced the launch of olanzapine tablets in the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths.
The drug is a generic version of Eli Lilly’s Zyprexa, used to treat schizophrenia and bipolar disorder. The branded drug and generic versions had sales of $3.28 billion during the 12-month period ended in January, according to IMS Health.
NCPA addresses PDUFA reauthorization
ALEXANDRIA, Va. — The National Community Pharmacists Association has sent a letter to a Senate committee regarding legislation that would reauthorize the Prescription Drug User Fee Act.
In its letter to the Senate Health, Labor, Education and Pensions Committee chairman Tom Harkin, D-Iowa, and ranking member Mike Enzi, R-Wyo., NCPA submitted recommendations to address the views of local pharmacists and NCPA responded to a "manager’s amendment" that would revise the legislation. The organization said its comments focused principally on prescription drug shortages and supply chain integrity.
"We believe the current pharmaceutical supply chain in the United States is safe and secure," NCPA CEO Douglas Hoey said. "As we strive to further strengthen security, there are a number of different approaches or tactics that could be employed. In addition, while most reported drug shortages to date have occurred in hospital settings, community pharmacies are also experiencing shortages, primarily in drugs that treat ADHD. The effects of these shortages could be mitigated by reforming the Drug Enforcement Agency’s quota system and by ensuring that pharmacy reimbursement rates are updated more frequently to reflect price spikes and keep pharmacies whole. In these and other areas, we look forward to continuing to work constructively with Congress as a PDUFA reauthorization is enacted into law this year."
To view the complete letter, click here.